OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in combination with Zytiga® in Men with

   OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of
OGX-427 in combination with Zytiga® in Men with Metastatic Castrate-Resistant
                               Prostate Cancer

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, Dec. 19, 2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Dec. 19, 2012 /PRNewswire/
--OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the
initiation of PACIFIC, an investigator-sponsored, randomized Phase 2 study
evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer
(CRPC) who are experiencing a rising PSA while receiving Zytiga (abiraterone
acetate). The aim of the study is to determine if adding OGX-427 to Zytiga
treatment can reverse or delay treatment resistance.

Approximately 80 men who are being treated with Zytiga and have evidence of a
rising PSA, but no evidence of symptomatic or radiographic progression, will
be randomized to either continue treatment with Zytiga and prednisone alone,
or have OGX-427 added to the Zytiga and prednisone treatment. Patients will be
stratified based on whether they have received prior chemotherapy and will
continue on study until symptomatic, radiographic or other documented disease
progression occurs. The primary objective will be to compare the two treatment
groups for delaying further disease progression while on Zytiga by assessing
the progression-free survival (PFS) rate at 60 days after adding OGX-427.
Secondary objectives include comparing the treatment arms for PSA responses,
objective responses, time to progression, circulating tumor cells (CTCs) and
other biomarkers.

"The rationale for PACIFIC is based on the idea that resistance to treatment
is caused by cancer cells using adaptive pathways to escape and proliferate,"
said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "OGX-427
and Zytiga are potentially synergistic because they disrupt androgen receptor
signaling in different ways. We believe that by adding OGX-427 to Zytiga in
patients who are experiencing a rising PSA we may be able to reverse treatment
resistance and extend the benefits of Zytiga."

PACIFIC will be conducted at approximately 15 sites in the US and Canada and
is being managed by the Hoosier Oncology Group. Dr. Kim Chi from the British
Columbia Cancer Agency, Dr. Christopher Sweeney from the Dana Farber Cancer
Institute and Dr. Noah Hahn from the Indiana University Simon Cancer Center,
will serve as the primary investigators on the study. Dr Noah Hahn is also the
Chief Scientific Officer for the Hoosier Oncology Group.

About OGX-427 and The "ORCA" Program
OGX-427 is designed to inhibit the production of Heat Shock Protein 27
(Hsp27), a cell-survival protein found at elevated levels in many human
cancers including prostate, bladder, breast and non-small cell lung cancer.
Overexpression of Hsp27 is thought to be an important factor leading to the
development of treatment resistance and is associated with negative clinical
outcomes in patients with various tumor types. The "ORCA" (On-going studies
evaluating treatment Resistance in CAncer) program encompasses clinical
studies aiming to demonstrate that inhibition of Hsp27 can lead to improved
prognosis and treatment outcomes for cancer patients. For more information on
OGX-427 and ORCA, please visit www.oncogenex.com.

About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in
Phase 2 clinical development and OGX-225 is currently in pre-clinical
development.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning our anticipated
product development activities, such as expected clinical trial completion and
statements regarding the potential benefits and potential development of our
product candidates. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements. These
statements are based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements. Such forward-looking statements are subject to
risks and uncertainties, including, among others, the risk that our product
candidates will not demonstrate the hypothesized or expected benefits, the
risk of delays in our expected clinical trials, the risk that new developments
in the rapidly evolving cancer therapy landscape require changes in our
clinical trial plans or limit the potential benefits of our product, the risk
that our cash resources are insufficient to fund our planned activities for
the time period expected and the other factors described in our risk factors
set forth in our filings with theSecurities and Exchange Commissionfrom time
to time, including the Company's Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. The Company undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be required
by applicable law.

Zytiga is a registered trademark of theJohnson & Johnson Corporation



SOURCE OncoGenex Pharmaceuticals, Inc.

Website: http://oncogenex.com
Contact: Jaime Welch, jwelch@oncogenex.com, +1-604-630-5403; or Investor
Relations Contact, Susan Specht, sspecht@oncogenex.com, +1-425-686-1535
 
Press spacebar to pause and continue. Press esc to stop.